Novo Nordisk A/S
NVOToday
-5.58%
5 Days
-7.20%
1 Month
-15.09%
6 Months
-33.23%
Year to Date
-47.72%
1 Year
-57.20%
TradingKey Stock Score of Novo Nordisk A/S
Currency: USD Updated: 2025-11-24Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Novo Nordisk A/S's Score
Support & Resistance
Score Analysis
Analyst Rating
Novo Nordisk A/S Highlights
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
Novo Nordisk A/S News
Novo Nordisk's obesity drug shows weight loss of up to 14.5% in mid-stage study
Nov 25 (Reuters) - Novo Nordisk NOVOb.CO said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study.
Biogen rises after Novo Nordisk's drug fails to meet main goal in Alzheimer's trials
Shares of Biogen BIIB.O rise 5.1% to $184.25 premarket
Eli Lilly vs. Novo Nordisk: Why Lilly Is Better Positioned Under Trump's Drug Pricing Pressure
TradingKey - Eli Lilly and Novo Nordisk, the two dominant players in the US weight-loss drug market, are experiencing vastly different investor sentiment despite facing unprecedented GLP-1 drug price cuts under the Trump administration's price cut initiative.
Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits
NEW YORK/LONDON, Nov 8 (Reuters) - U.S. drugmaker Pfizer has PFE.N clinched a $10 billion deal for obesity drug developer Metsera MTSR.O, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk NOVOb.CO.
“Trump’s Pharmacy” Cutting Weight-Loss Drug Prices — What This Means for Novo and Lilly
TradingKey - Following agreements with Pfizer and AstraZeneca, the so-called “twin giants” of weight-loss drugs — Novo Nordisk and Eli Lilly — have now also reached pricing deals with the Trump administration. This marks the latest move in Trump’s broader push to cut U.S. drug prices by up to 90%
Novo Nordisk, Lilly strike deal with Trump to slash weight-loss drug prices
WASHINGTON, Nov 6 (Reuters) - U.S. President Donald Trump, Eli Lilly LLY.N and Novo Nordisk NOVOb.CO unveiled a deal on Thursday to slash the prices of popular GLP-1 weight‑loss drugs for the government's Medicare and Medicaid programs, as well as for cash payers.
Financial Indicators
EPS
Total revenue
Novo Nordisk A/S Info
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
FAQs
What is the current price of Novo Nordisk A/S (NVO)?
What is the symbol of Novo Nordisk A/S?
What is the 52-week high of Novo Nordisk A/S?
What is the 52-week low of Novo Nordisk A/S?
What is the market capitalization of Novo Nordisk A/S?
What is the net income of Novo Nordisk A/S?
Is Novo Nordisk A/S (NVO) currently rated as Buy, Hold, or Sell?
What is the Earnings Per Share (EPS TTM) of Novo Nordisk A/S (NVO)?
Related Instruments
Popular Symbols
